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Abstract
Radical nephroureterectomy (RNU) represents the standard of care for high-risk upper tract urothelial carcinoma
(UTUC). In selected patients with ureteral UTUC, a conservative approach such as segmental ureterectomy (SU) can
be considered. However, this therapeutic option remains controversial. The aim of this study was to perform a sys-
tematic review and meta-analysis of studies assessing the outcomes of SU versus RNU in patients with UTUC. Three
search engines (Scopus, Embase, and Web of Science) were queried up to May 2019. The Preferred Reporting Items
for Systematic Review and Meta-analysis Statement (PRISMA Statement) was used as a guideline for study selection.
The clinical question was established as stated in the PICO (Population, Intervention, Comparator, Outcome) process.
Patients in the SU group were more likely to have history of bladder cancer (odds ratio [OR], 1.99; 95% confidence
interval [CI], 1.12-3.51; P ¼ .02), but less likely to present with preoperative hydronephrosis (OR, 0.52; 95% CI:
0.31-0.88; P ¼ .02). A higher rate of ureteral tumor location was found in the SU group (OR, 7.54; 95% CI, 4.15-13.68;
P < .00001). The SU group presented with a lower rate of higher (pT  2) stage (OR, 0.66; 95% CI, 0.53-0.82;
P ¼ .0002), and high-grade tumors (OR, 0.62; 95% CI, 0.50-0.78; P < .0001). The SU group was found to have shorter
5-year relapse-free survival (OR, 0.64; 95% CI, 0.43-0.95; P ¼ .03), but higher postoperative estimated glomular
filtration rate (weighted mean difference, 10.97 mL/min; 95% CI, 2.97-18.98; P ¼ .007). Selected patients might benefit
from SU as a therapeutic option for UTUC. In advanced high-risk disease, RNU still remains the standard of care.
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Radical nephroureterectomy (RNU) with bladder cuff excision
remains the standard of care for high-risk upper tract urothelial
carcinoma (UTUC).1 Traditionally, more conservative management
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Clinical Genitourinary Cancer February 2020anatomical/functional conditions requiring kidney-sparing surgery
(solitary kidney, baseline chronic kidney disease, or bilateral pa-
thology).2 Several kidney-sparing surgery techniques have been
described and implemented, but their oncologic safety remains
debatable.3,4
In this setting, segmental ureterectomy (SU) represents an option
in selected patients, such as those with low-risk ureteral tumors or
those with high-risk disease who might benefit from a conservative
approach.5 The aim of this study was to perform a systematic review
and meta-analysis of comparative studies assessing the oncologic
outcomes of SU versus RNU.
Material and Methods
Literature Research Strategy
Two authors (A.V. and E.C.) screened literature regarding SU
versus RNU. The results were assessed by a third author (R.A.).
Three search engines (Scopus, Embase, and Web of Science) were1558-7673/$ - see frontmatter ª 2019 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.clgc.2019.10.015
queried up to May 2019. The following strategy was deemed as the
best for this study: ((((segmental ureterectomy) OR partial ureter-
ectomy) OR distal ureterectomy) OR kidney sparing ureterectomy)
AND nephroureterectomy).
The time frame of the included studies ranged from 2000 to
2019. The research was focused on English language studies and did
not include conference abstracts, conference papers, notes, letters,
editorials, and short surveys. Reviews were included only to screen
the reference list to avoid missing articles.
Study Selection
The Preferred Reporting Items for Systematic Review and Meta-
analysis Statement (PRISMA Statement; www.prisma-statement.
org)6 was used as a guideline for study selection. The clinical
question was established as stated in the PICO (Population, Inter-
vention, Comparator, Outcome) process7: patients with UTUC (P)Figure 1 Preferred Reporting Items for Systematic Reviews and Meundergoing SU (I) or RNU (C) to compare pathologic and survival
outcomes (O).
First, the title of the studies was evaluated to exclude those
inconsistent with the PICO question. Second, the abstracts of each
potentially eligible study were carefully assessed, and those meeting
the eligible criteria were included.Data Extraction
Data included in the meta-analysis were the following:
(1) Baseline features: age, gender (male), race (Caucasian),
current smoking history, American Society of Anesthesiol-
ogists score  3, history of bladder cancer, tumor side
(right), tumor location (pelvicalyceal and ureteral);
(2) Pathologic outcomes: pT  2, tumor grade (high-grade),
Nþ, associated Tis, positive surgical margins;ta-Analyses (PRISMA) Flow Chart
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Table 1 Characteristics of the Studies
Author Study Period Centers Study Design SU RNU Endpoints LE SQ
Giannarini et al13 1974-2004 Single Retrospective analysis 19 24 - Pathologic outcomes
- Survival outcomes
3 *******
Jeldres et al14 1988-2004 SEER Database Retrospective analysis 569 1475 - Pathologic outcomes
- Survival outcomes
3 ******
Silberstein et al15 1994-2009 Single Retrospective analysis 33 87 - Pathologic outcomes
- Survival outcomes
3 ******
Colin et al16 1995-2009 Multiple Retrospective analysis 52 416 - Pathologic outcomes
- Survival outcomes
2 *******
Bin et al17 2000-2010 Single Case series 17 33 - Pathologic outcomes
- Survival outcomes
4 *******
Bagrodia et al18 - Single Retrospective analysis 81 754 - Pathologic outcomes
- Survival outcomes
3 ******
Dalpiaz et al19 1984-2011 Single Retrospective analysis 49 42 - Pathologic outcomes
- Survival outcomes
3 *******
Hung et al20 2004-2010 Single Retrospective analysis 35 77 - Pathologic outcomes
- Survival outcomes
3 *******
Fukushima et al21 - Multiple Retrospective analysis 43 86 - Pathologic outcomes
- Survival outcomes
3 *******
Pedrosa et al22 1999-2012 Single Retrospective analysis 45 96 - Pathologic outcomes
- Survival outcomes
3 *******
Singla et al23 1998-2012 Multiple Retrospective analysis 50 143 - Functional outcomes
- Survival outcomes
3 ******
Seisen et al24 2004-2013 Multiple Retrospective analysis 134 128 - Pathologic outcomes
- Survival outcomes
3 *******
Fang et al25 2003-2016 Single Retrospective analysis 53 78 - Pathologic outcomes
- Survival outcomes
3 *******
Huang et al26 2011-2016 Single Retrospective analysis 24 39 - Functional outcomes
- Survival outcomes
3 ******
Zhang et al27 2005-2016 Single Retrospective analysis 38 109 - Surgical outcomes
- Survival outcomes
3 ******
Kato et al28 2004-2016 Single Retrospective analysis 12 14 - Pathologic outcomes
- Survival outcomes
3 ******
Jia et al29 2000-2014 Single Retrospective analysis 40 179 - Pathologic outcomes
- Survival outcomes
3 *******












































































Alessandro Veccia et al(3) Survival outcomes: adjuvant chemotherapy, recurrence
(overall and bladder), metastasis, cancer-related death, 5-year
recurrence-free survival (RFS), metastasis-free survival
(MFS), and cancer-specific survival (CSS), hazard ratio (HR)
of RFS, and CSS surgical technique related (SU vs. RNU);
(4) Functional outcomes: preoperative estimated glomerular




































































































































































































































Level of evidence as stated in the Oxford Level of Evidence
Working Group 2011 was used to stratify each study.8 The
Newcastle-Ottawa Assessment Scale for non-randomized controlled
trials was used to evaluate the studies’ quality.9 A score of 5 was
considered low, 6 to 7 intermediate, and 8 to 9 high quality. The
bias assessment was performed using the Cochrane Collaboration
Risk of Bias Tool.10
Data Analysis
Continuous and dichotomous variables were considered: inverse
variance weight mean difference (WMD) was used to summarize
continuous variables, whereas the Mantel-Haenszel test was used to
calculate odds ratios (ORs) with 95% confidence intervals (CIs) of
binary values. The random effect model was deemed most suitable
to evaluate the cumulative heterogeneity among the studies.11 The
level of heterogeneity was stratified as low ( 25%), intermediate
(26%-75%), and high (> 75%). Given the possibility to perform
cumulative analysis of mean  standard deviation (SD) only, me-
dian (range) was converted to mean  SD through the Hozo for-
mula.12 Cumulative analysis of HR (CI) was performed after
extraction of lnHR and calculation of standard error (SE). Then, we
performed a sensitivity analysis of 5-year RFS and CSS of those
studies of distal tumors treated with SU and RNU.
Statistical pooled analyses were performed using Review Manager
(RevMan) (Version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). Statistical significance





























































































































































































































































Features of the Studies
Figure 1 reports the study selection PRISMA flow chart. Eigh-
teen comparative studies were deemed eligible for meta-anal-
ysis.13-30 No randomized controlled trial was available, all the
studies were retrospective, and only one was prospective.16 All the
studies included were of intermediate quality.
Overall, the meta-analysis included 4797 patients (1313 patients
in the SU group and 3484 patients in the RNU group) (Table 1).
Baseline Features
No statistically significant differences in terms of age, gender, race,
smoking history, and American Society of Anesthesiologists score were
recorded.More patients in the SUgroup had a history of bladder cancer
(OR, 1.99; 95% CI, 1.12-3.51; P ¼ .02)13,15,16,19-22,25,26,28,30 but a
lower probability of preoperative hydronephrosis (OR, 0.52; 95% CI,
0.31-0.88; P ¼ .02).13,15,19,21,24-26 A higher rate of ureteral tumor
location was found in the SU group (OR, 7.54; 95% CI, 4.15-13.68;
P < .00001)18,28,30 (Table 2).Clinical Genitourinary Cancer February 2020 - e13
Figure 2 Pathologic Outcomes
Abbreviations: CI ¼ confidence interval; M-H ¼ Mantel-Haenszel; RNU ¼ radical nephroureterectomy; SU ¼ segmental ureterectomy.
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Patients in the SU group had less advanced disease, with a lower
rate of pT  2 (OR, 0.66; 95% CI, 0.53-0.82; P ¼ .0002)13-30 and
high-grade tumors (OR, 0.62; 95% CI, 0.50-0.78; P < .0001).13-30
No statistically significant difference was recorded in terms of pos-
itive surgical margin (Figure 2).
Survival Outcomes
No statistically significant difference was found between the SU
andRNUgroups in terms of recurrence (overall [P¼ .13] and bladder
[P¼ .50]), metastasis (P ¼ .18), and cancer-related death (P¼ .95).
No statistically significant difference was found regarding adjuvant
chemotherapy. The SU group showed lower 5-year RFS (OR, 0.64;
95%CI, 0.43-0.95;P¼ .03).16,18-21,24,26,28,29 This was confirmed in
the cumulative analysis of HRs, where the RNU group was associated
with higher RFS (HR, 1.26; 95%CI, 1.07-1.49; P¼ .006).16,21,24,29
On the other hand, there was no statistically significant difference in
terms 5-year MFS and CSS (Figure 3). Survival analysis of distal tu-
mors showed no statistically significant difference in terms of 5-year
RFS and CSS between the SU and RNU groups (Figure 4).
Functional Outcomes
No statistically significant difference was found in preoperative
eGFR, whereas the SU group showed higher postoperative eGFR
(WMD, 10.97 mL/min; 95% CI, 2.97-18.98; P ¼ .007).21,23,26-28
Despite the fact that SU seemed to be clinically associated with an
improvement of eGFR, it did not achieve the conventional level of
statistical significance (WMD, 7.18 mL/min; 95%CI, 1.68 to
16.04; P ¼ .11)20,21,23,26,29 (Table 3).
Publications Bias
Overall, each study was affected by a high risk of selection,
performance, and detection bias. No other obvious bias was clearlyClinical Genitourinary Cancer February 2020recognizable (see Supplemental Figures 1 and 2 in the online
version).
Discussion
Herein we present the largest analysis assessing pathologic and
survival outcomes of SU versus RNU in patients with UTUC.
Compared with the most recent systematic review on this
topic,31 we included 6 additional studies for a total of 18
studies. Our findings give rise to some interesting points of
discussion.
The SU and RNU groups had similar baseline characteristics, but
there was a higher rate of patients with history of bladder cancer in
the SU group. This finding is consistent with previous literature.
Silberstein et al conducted a comparative analysis of SU versus RNU
and found 70% of patients who underwent SU had a previous his-
tory of bladder cancer.15 Recently, a multicenter analysis on robotic
SU versus RNU found a history of bladder cancer in 40% of the SU
cases.30 Moreover, this higher rate could be owing to bladder tumor
seeding when localized near ureteral orifices.19 As expected, we
found that SU was mostly performed in patients with ureteral car-
cinoma, and this was consistently reported in all the studies.18,28,30
Preoperative hydronephrosis was more frequent in the RNU
group. Kohada et al assessed the impact of hydronephrosis and
elevated neutrophil/lymphocyte ratio within a cohort of 148 patients
undergoing RNU and found that these parameters were associated
with advanced pathologic stage.32 Our analysis indirectly confirms
this finding, as RNU patients were more likely to present with
preoperative hydronephrosis but also to have more advanced disease.
To note, 6 studies reported similar pathologic stage between the 2
groups,13,16,17,20,28,30 but this was not the case for the tumor
grading, which was similar in only 2 reports.16,25 The advanced
disease stage did not translate into any difference in terms of CSS,
but the SU group had a shorter RFS. Several factors might explain
Figure 3 Survival Outcomes
Abbreviations: CI ¼ confidence interval; CSS ¼ cancer-specific survival; MFS ¼ metastasis-free survival; M-H ¼ Mantel-Haenszel; RFS ¼ relapse-free survival; RNU ¼ radical nephroureterectomy;
SU ¼ segmental ureterectomy.
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Figure 4 Survival Outcomes Distal Ureterectomy
Abbreviations: CI ¼ confidence interval; CSS ¼ cancer-specific survival; M-H ¼ Mantel-Haenszel; RFS ¼ relapse-free survival; RNU ¼ radical nephroureterectomy; SU ¼ segmental ureterectomy.
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e16 -this finding. As recommended by current guidelines, SU can be
offered for high-grade tumors distally located in the ureter.1 On the
other hand, ureteral tumor location, especially distal location, as well
as previous history of bladder cancer, was shown to be associated
with shorter RFS.33 These characteristics perfectly mirror those of
the patients in the SU group of our analysis.
In addition, the lack of strong evidence regarding survival out-
comes for SU requires a strict follow-up for these patients, with
periodic ureterorenoscopies.4 The literature has already highlighted
the negative impact of diagnostic ureteroscopy on prognosis.
Indeed, has been hypothesized that the application of high endo-
luminal pressure during the procedure might be responsible of
pyelolymphatic and pyelovenous backflow, which could explain
tumor seeding.34 Marchioni et al corroborated this hypothesis
within a systematic review and meta-analysis regarding the impact of
diagnostic ureterorenoscopy (URS) on intravesical recurrence. With
a pooled analysis of 5 retrospective comparative studies, they
underlined a higher hazard of recurrence in those patients under-
going URS.35 Despite this, we could not assess the use of preop-
erative URS because it was not routinely used in all the studies
included. Another proof of the lower RFS in the SU group was the
finding of a statistically significant association of RNU with RFS
(HR, 1.26; 95% CI, 1.07-1.49; P ¼ .006). This was not the case
for SU and RNU performed for distal tumors. Sensitivity analysis
showed no statistically significant difference between the 2 pro-
cedures, and this was consistent with previous evidence. Dalpiaz
et al compared SU and RNU for distal urothelial tumors and found
5-year CSS and RFS rates of 77% and 91% for SU and 78% and
96% for RNU, respectively.19 Again, Seisen et al compared distal
ureterectomy and RNU and achieved the same results as our meta-
analysis.24Clinical Genitourinary Cancer February 2020Regarding functional outcomes, not surprisingly, SU was found
to be associated with better postoperative eGFR compared with
RNU. Indeed, our pooled analysis showed a higher level of eGFR,
and an improvement of eGFR in the SU group (albeit this was
statistically significant).
The above-mentioned finding might help to establish the best
treatment tailored to each patient. Indeed, some patients might need
adjuvant chemotherapy after surgery, and kidney function preserva-
tion could bemandatory.36 On the other hand, in some cases, RNU is
the only possible option, and in these cases, neoadjuvant therapy
should be considered.37 In our analysis, 16% of SU patients and
15% of RNU patients received adjuvant chemotherapy (P ¼ .97).
To the best of our knowledge, this is the largest and most
updated systematic review and meta-analysis on SU versus RNU.
Despite this, some intrinsic limits require its results to be interpreted
cautiously. Indeed, the retrospective nature of the studies makes it
subject to selection and reporting bias. In addition, it was not
possible to account for the surgical techniques used, and this might
have influenced the results. Furthermore, this analysis address only
the comparison of SU and RNU and does not consider other
conservative techniques.3 Another important limitation was the
impossibility of stratifying the surgical techniques according to tu-
mor position, so the results give a partial view of the picture. Indeed,
only 4 studies reported survival outcomes of distal ureterectomy
compared with RNU, but their limited number did not enable us to
draw meaningful conclusions.19,21,24,29 Moreover, it was not
possible to discriminate standard distal SU (bladder cuff and ure-
teroneocystostomy) from a true SU (portion of ureter excision with
uretero-ureterostomy). Notwithstanding these limitations, the re-
sults achieved suggest that both treatments could provide at least











































































































































































































































































Alessandro Veccia et alConclusions
SU can be considered as a treatment option for patients with
UTUC in selected cases as it offers better preservation of renal
function. However, a strict follow-up is mandatory in these cases to
avoid jeopardizing the oncologic outcome. In advanced high-risk
disease, RNU remains the standard of care. The evidence in this
field is based on intermediate- to low-quality non-randomized
studies, and further research efforts are warranted.
Disclosure
The authors have stated that they have no conflicts of interest.
Supplemental Data
Supplemental figures accompanying this article can be found in
the online version at https://doi.org/10.1016/j.clgc.2019.10.015.
References
1. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology
Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol
2018; 73:111-22.
2. Raman JD. Kidney sparing surgery for upper-tract urothelial carcinoma. Minerva
Urol Nefrol 2016; 68:359-71.
3. Territo A, Foerster B, Shariat SF, et al. Diagnosis and kidney-sparing treatments
for upper tract urothelial carcinoma: state of the art.Minerva Urol Nefrol 2018; 70:
242-51.
4. Gakis G, Schubert T, Alemozaffar M, et al. Update of the ICUD-SIU consultation
on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.
World J Urol 2017; 35:327-35.
5. Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of
kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial
carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer
Guidelines Panel. Eur Urol 2016; 70:1052-68.
6. Moher D, Shamseer L, Clarke M, et al, PRISMA-P Group. Preferred reporting
items for systematic review and meta-analysis protocols (PRISMA-P) 2015 state-
ment. Syst Rev 2015; 4:1.
7. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical
question: a key to evidence-based decisions. ACP J Club 1995; 123:A12-3.
8. Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre
for Evidence-Based Medicine (OCEBM) Levels of Evidence (background docu-
ment). Oxford Centre for Evidence-Based Medicine, Available at: http://www.
cebm.net/index.aspx?o¼5653. Accessed: July 23, 2019.
9. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomized studies in meta-analyses. Ottawa
Hosp Res Inst 2013:1. http://www.ohri.ca/programs/clinical_epidemiology/oxford.
asp. Accessed: July 23, 2019.
10. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assess-
ment of study quality for systematic reviews: a comparison of the Cochrane
Collaboration Risk of Bias Tool and the Effective Public Health Practice
Project Quality Assessment Tool: methodological research. J Eval Clin Pract
2012; 18:12-8.
11. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in
decision models. Med Decis Making 2005; 25:646-54.
12. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the
median, range, and the size of a sample. BMC Med Res Methodol 2005; 5:13.
13. Giannarini G, Schumacher MC, Thalmann GN, Bitton A, Fleischmann A,
Studer UE. Elective management of transitional cell carcinoma of the distal ureter:
can kidney-sparing surgery be advised? BJU Int 2007; 100:264-8.
14. Jeldres C, Lughezzani G, Sun M, et al. Segmental ureterectomy can safely be
performed in patients with transitional cell carcinoma of the ureter. J Urol 2010;
183:1324-9.
15. Silberstein JL, Power NE, Savage C, et al. Renal function and oncologic outcomes
of parenchymal sparing ureteral resection versus radical nephroureterectomy for
upper tract urothelial carcinoma. J Urol 2012; 187:429-34.
16. Colin P, Ouzzane A, Pignot G, et al, French Collaborative National Database on
U.U.T.-U.C.. Comparison of oncological outcomes after segmental ureterectomy
or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract:
results from a large French multicentre study. BJU Int 2012; 110:1134-41.
17. Bin X, Roy OP, Ghiraldi E, et al. Impact of tumour location and surgical approach
on recurrence-free and cancer-specific survival analysis in patients with ureteric
tumours. BJU Int 2012; 110:E514-9.
18. Bagrodia A, Kuehhas FE, Gayed BA, et al. Comparative analysis of oncologic
outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract
urothelial carcinoma. Urology 2013; 81:972-7.
19. Dalpiaz O, Ehrlich G, Quehenberger F, Pummer K, Zigeuner R. Distal ureter-
ectomy is a safe surgical option in patients with urothelial carcinoma of the distal
ureter. Urol Oncol 2014; 32:34.e1-8.Clinical Genitourinary Cancer February 2020 - e17
Segmental Ureterectomy for Upper Urothelial Carcinoma
e18 -20. Hung SY, Yang WC, Luo HL, Hsu CC, Chen YT, Chuang YC. Segmental
ureterectomy does not compromise the oncologic outcome compared with
nephroureterectomy for pure ureter cancer. Int Urol Nephrol 2014; 46:921-6.
21. Fukushima H, Saito K, Ishioka J, et al. Equivalent survival and improved pres-
ervation of renal function after distal ureterectomy compared with nephroureter-
ectomy in patients with urothelial carcinoma of the distal ureter: a propensity
score-matched multicenter study. Int J Urol 2014; 21:1098-104.
22. Pedrosa JA, Masterson TA, Rice KR, et al. Oncologic outcomes and prognostic
impact of urothelial recurrences in patients undergoing segmental and total ure-
terectomy for upper tract urothelial carcinoma. Can Urol Assoc J 2015; 9:E187-92.
23. Singla N, Gayed BA, Bagrodia A, et al. Multi-institutional analysis of renal
function outcomes following radical nephroureterectomy and partial ureterectomy
for upper tract urothelial carcinoma. Urol Oncol 2015; 33:268.e1-7.
24. Seisen T, Nison L, Remzi M, et al. Oncologic outcomes of kidney sparing surgery
versus radical nephroureterectomy for the elective treatment of clinically organ
confined upper tract urothelial carcinoma of the distal ureter. J Urol 2016; 195:
1354-61.
25. Fang C, Xie X, Xu T, et al. Segmental ureterectomy is not inferior to radical
nephroureterectomy for either middle or distal ureter urothelial cell carcinomas
within 3.5 cm. Int Urol Nephrol 2017; 49:1177-82.
26. Huang Z, Zhang X, Zhang X, et al. Segmental ureterectomy is acceptable for high-
risk ureteral carcinoma comparing to radical nephroureterectomy. J Invest Surg
2018; 25:1-8.
27. Zhang J, Yang F, Wang M, Niu Y, Chen W, Xing N. Comparison of radical
nephroureterectomy and partial ureterectomy for the treatment of upper tract
urothelial carcinoma. Biomed Res Int 2018; 2018:2793172.
28. Kato T, Nakayama R, Haba T, Kawaguchi M, Komiya A, Koike H. Oncological
and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for
upper tract urothelial carcinoma. Oncol Lett 2018; 16:6861-7.Clinical Genitourinary Cancer February 202029. Jia Z, Gong Y, Zhang C, et al. Segmental ureterectomy can be performed safely in
patients with urothelial carcinoma of distal ureter. Can Urol Assoc J 2018; 20:
E202-9.
30. Campi R, Cotte J, Sessa F, et al. Robotic radical nephroureterectomy and segmental
ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience
[e-pub ahead of print], World J Urol. 2019. doi:10.1007/s00345-019-02790-y.
31. Fang D, Seisen T, Yang K, et al. A systematic review and meta-analysis of onco-
logical and renal function outcomes obtained after segmental ureterectomy versus
radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol
2016; 42:1625-35.
32. Kohada Y, Hayashi T, Goto K, et al. Preoperative risk classification using
neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carci-
noma. Jpn J Clin Oncol 2018; 48:841-50.
33. Xylinas E, Kluth L, Passoni N, et al, UTUC Collaboration. Prediction of intra-
vesical recurrence after radical nephroureterectomy: development of a clinical
decision-making tool. Eur Urol 2014; 65:650-8.
34. Lim DJ, Shattuck MC, Cook WA. Pyelovenous lymphatic migration of tran-
sitional cell carcinoma following flexible ureterorenoscopy. J Urol 1993; 149:
109-11.
35. Marchioni M, Primiceri G, Cindolo L, et al. Impact of diagnostic ureteroscopy on
intravesical recurrence in patients undergoing radical nephroureterectomy for up-
per tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017;
120:313-9.
36. Kaag MG, O’Malley RL, O’Malley P, et al. Changes in renal function following
nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol
2010; 58:581-7.
37. Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based neoadjuvant
chemotherapy improves oncological outcomes in patients with locally advanced
upper tract urothelial carcinoma. Eur Urol Focus 2018; 4:946-53.
Supplemental Figure 1 Risk of Bias Graph. Review Authors’ Judgments About Each Risk of Bias Item Presented as Percentages
Across all Included Studies
Alessandro Veccia et al
Clinical Genitourinary Cancer February 2020 - e19
Supplemental Figure 2 Risk of Bias Summary. Review
Authors’ Judgments About Each Risk
of Bias Item for Each Included Study
Segmental Ureterectomy for Upper Urothelial Carcinoma
e20 - Clinical Genitourinary Cancer February 2020
